secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001651308-24-000055
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene shareholders approve equity plan share increases and director re-elections at AGM
--------------------------------------------------------------------------------

- Approved Third Amended 2016 Share Option Plan, adding 92.82M shares to the reserve.
- Approved Fourth Amended 2018 ESPP, increasing share availability by 5.07M shares.
- Re-elected Class II directors Brandicourt, Glazer, Goller, Sanders with strong support.
- Approved general mandates to issue up to 20% and repurchase up to 10% of shares.
- Approved RSUs and PSUs to CEO John Oyler ($6M each) and other executive grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000055/0001651308-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000055/bgne-20240605.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer